MyControl – a new website about obesity for HCP and patients
With our new website Mycontrol, we hope to increase knowledge about obesity among the general public and healthcare professionals. The site, which highlights causes, risks and the benefits of a long-term weight loss, places great focus on the brain’s role in developing and mastering the disease and, in addition to current treatment options, also addresses the importance of the right treatment. The website is available in Norwegian, Swedish, Danish & Finnish.
Sign up for Navamedics newsletter on obesity to get the latest news and research within the obesity area.
Obesity is as a chronic disease in which excess body fat has accumulated to an extent that it may have a negative effect on health. Obesity increases the likelihood of various diseases and conditions, particularly cardiovascular diseases, type 2 diabetes, obstructive sleep apnea, certain types of cancer, osteoarthritis, and depression. People are generally considered obese when their body mass index (BMI), a measurement obtained by dividing a person’s weight by the square of the person’s height, is over 30 kg/m2; the range 25–30 kg/m2 is defined as overweight.
Between 15-23% of the Nordic population are obese and the cost of treating obesity-related complication are enormous. Only in Sweden the estimated cost for treating obesity is 70 billion yearly. 
Unfortunately, physiological adaptations to weight loss favour weight regain. These changes include perturbations in the levels of circulating appetite-related hormones and energy homoeostasis, in addition to alterations in nutrient metabolism and subjective appetite. To maintain weight loss, individuals must adhere to behaviours that counteract physiological adaptations and other factors favouring weight regain. It is difficult to overcome physiology with behaviour, why medications, and sometimes surgery, are the best treatment alternatives for many patients. (5)
Navamedic contributes to obesity management by providing top of the line pharmaceutical treatment that can help patients lose weight and keep a lower weight. Navamedic also educates healthcare personnel in obesity management.
- Obesity and overweight Fact sheet. WHO. January 2018. Retrieved 10 February 10, 2020.
- Haslam DW, James WP (October 2005). “Obesity”. Lancet (Review). 366 (9492): 1197–209. doi:10.1016/S0140-6736(05)67483-1. PMID 16198769.
- Luppino FS, de Wit LM, Bouvy PF, Stijnen T, Cuijpers P, Penninx BW, Zitman FG (March 2010). “Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies”. Archives of General Psychiatry. 67 (3): 220–9.
- Folkhälsomyndigheten https://www.folkhalsomyndigheten.se/livsvillkorlevnadsvanor/
- Greenway FL. Physiological adaptations to weight loss and factors favouring weight regain. Int J Obes (Lond) 201:39 (8)
Mysimba is a medicine used along with diet and exercise to help manage weight in adults:
• who are obese (have a body-mass index – BMI – of 30 or more);
• who are overweight (have a BMI between 27 and 30) and have weight-related complications such as diabetes, abnormally high levels of fat in the blood, or high blood pressure.
BMI is a measurement that indicates body weight relative to height.
Mysimba contains the active substances naltrexone and bupropion, which are licensed individually in the EU for other uses.
The exact way that Mysimba works is not fully understood, but the two active substances, naltrexone and bupropion, act on the parts of the brain that control food intake and energy balance, as well as reducing the effect of the part of the brain that controls the pleasure associated with eating food. When given together, their actions reduce appetite and the amount that patients eat, and increase energy expenditure, helping them to stick to a calorie-controlled diet and to reduce their body weight.
The effect of Mysimba has been proven in four randomised, controlled trials. Patients using My-simba averagely lose 4-5 times as much weight as a patient on placebo medication (1). 50% of patients respond to Mysimba, with a mean weight loss of 11,5 %, one year after starting the medication (2). To be qualified as a responder, the patient needs to lose 5% of initial body weight within 16 weeks of the start of medication.
- Greenway et al (2010) Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2010 Aug 21;376(9741):595-605.
- Fujioka et al (2016). The relationship between early weight loss and weight loss at 1 year with naltrexone ER/bupropion ER combination therapy. Int J Obes (Lond). 2016 Sep;40(9):1369-75
For extended product information, please visit: